Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer
In this podcast, Helena Yu, MD, discusses recent advances in the field of antibody–drug conjugates and the current rationale for targeting HER3 for treatment of non-small-cell lung cancer.
Decera Clinical Education Oncology Podcast · Helena Yu MD, Rebecca S. Heist MD MPH
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs.
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.